Latest Product Pipeline News

Bio-Gene Technology Limited has completed the second tranche of its share placement, securing approximately A$2.46 million and issuing unlisted options to investors and its lead manager.

Atomo Diagnostics has successfully placed $260,000 of the shortfall from its recent Share Purchase Plan, issuing over 14 million shares and options to sophisticated investors. This capital injection strengthens the company’s working capital position as it advances its rapid diagnostic test business.

IKE GPS Group Limited has opened a A$2.0 million Share Purchase Plan following an A$18 million placement, aiming to accelerate product innovation and strategic expansion.

Compumedics Limited has reported record sales orders and a return to profitability in FY25, setting the stage for robust growth in FY26 driven by US market traction and SaaS expansion.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.

Zenith Minerals has announced a significant 41% increase in the inferred gold resource at its Dulcie Far North Project, now totaling 302,000 ounces. This milestone follows extensive drilling and strategic land consolidation, positioning the project for further growth.

HighCom Limited has recommissioned its XTclave™ system in Ohio, doubling production capacity and setting the stage for new ballistic product launches in FY26. The move strengthens its collaboration with the U.S. Department of Defense and positions the company for significant government contract opportunities.

Activeport Group has secured over $1.2 million in new Network-as-a-Service orders across Sydney and Melbourne, marking a strong market debut for its Global Edge platform. The company’s innovative self-service network offering is set to drive significant revenue growth in FY26.

CLINUVEL Pharmaceuticals announces the full-time return of Managing Director Dr Philippe Wolgen, focusing on advancing critical product development and corporate initiatives, while Acting CEO Lachlan Hay continues until September 2025.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

AnteoTech secures a significant purchase order from the Serum Institute of India, driving its Life Sciences unit toward a projected 130% sales increase in FY2025 despite some project delays.

Advance ZincTek Limited signals a strong financial turnaround for FY25, expecting a $1.75 million profit before tax driven by increased US sales and strategic operational shifts.